Skip to content
‹ Back to IndustriesHealthcare

High Costs, Low Margins, and Regulatory Hurdles Hinder Pharma’s Adoption of Advanced Manufacturing Technologies

Pharmaceutical manufacturers face financial and regulatory barriers that outweigh the benefits of modernizing their production processes

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Mike Tracy · · Advanced Manufacturing TechnologiesDrug ProductionDrug ShortageMike Tracy
Share

Key takeaways

01

Pharmaceutical manufacturers face financial and regulatory barriers that outweigh the benefits of modernizing their production processes

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The ongoing drug shortage crisis in the U.S. underscores a critical need for innovation in pharmaceutical manufacturing. As manufacturing issues, outdated technologies, and geopolitical risks contribute to shortages that impact patient care and elevate healthcare costs, the introduction of Advanced Manufacturing Technologies (AMTs) offers a beacon of hope. AMT technologies promise to enhance quality control and reduce production downtime, yet their adoption in generic drug production remains low despite obvious benefits.

Why is the pharmaceutical industry slow to adopt technologies that could revolutionize drug availability and cost?

Mike Tracy, a C-Level Healthcare Operations Strategist, dives into the complexities of integrating Advanced Manufacturing Technologies in drug production. Mike points out that while AMTs can drastically reduce bottlenecks in drug production, the significant initial investment and stringent regulatory landscape pose substantial hurdles.

“Every AMT has a high startup cost and generic drugs have very razor-thin margins to begin with. We’re not talking about a new drug that’s not already out in the market where you’re going to have a high margin and it makes sense to invest millions,” Tracy explains.

Every AMT has a high startup cost and generic drugs have very razor-thin margins to begin with.
— Mike Tracy, C-Level Healthcare Operations Strategist

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Mike Tracy
Mike TracyChief Operating Officer at enGen

With a fulfilling history within the healthcare industry, Mike establish thoughtful, metric-based direction for new and improved initiatives, processes, and programs to refresh employee engagement, satisfy customers, and revamp operational efficiencies. By employing effective cost analysis, he identify avenues for appropriate cost reductions without jeopardizing staffing and operation needs. For example, Mike accomplished a 20% reduction in SG&A cost for technology by engineering a standard operating model, automation development, and revising processes in my current position. Alongside expert cost analysis, he ensure all implementations align with company goals and missions while assessing community needs.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Siemens Healthineers starts carving out its 16-billion-test diagnostics business as Olyrian Diagnostics

Siemens Healthineers starts carving out its 16-billion-test diagnostics business as Olyrian Diagnostics

Siemens Healthineers has begun carving out its diagnostics business, which the company says makes more than 16 billion tests a year. The unit will take the name Olyrian Diagnostics, and the company expects the internal separation to be finished by mid-2028. Reuters reported that the rebrand comes ahead of a future divestment, though no buyer, listing or other structure has been named. As of the announcement, the company says contracts and service levels have not changed. For labs, the change is most likely to show up in agreements that run past mid-2028.

  • 01A lab contract that runs past mid-2028 could finish its term with Olyrian Diagnostics as the supplier.
  • 02The diagnostics unit is about one in five Siemens Healthineers employees, so the separation means building standalone functions, which is a bigger job than putting up a new logo.

Nov 17, 2026

Up to 0.864 in U.S. and Austrian ICUs, 0.698 in China

Up to 0.864 in U.S. and Austrian ICUs, 0.698 in China

ELDER-ICU, an ICU mortality prediction model for patients 65+, reached up to 0.864 AUROC in U.S. and Austrian cohorts but 0.698 at a site in China. The results highlight that performance can vary across settings, so hospitals buying AI built elsewhere should validate it on local patients and ensure contracts allow recalibration or retraining when needed.

  • 01A vendor's validation claim is only as good as the patients it was tested on: one ICU mortality model scored 0.804 to 0.864 AUROC in U.S. and Austrian hospitals and 0.698 in China.
  • 02Match the fix to the failure. Recalibration improved probability accuracy at every site, while only retraining on local data recovered the bigger ranking losses at the South Korean and Chinese sites (+0.066 and +0.076 AUROC).
  • 03Checking AI on local patients takes staff and contract terms: whether the license permits local recalibration or retraining, and who on the team can run it.

Nov 17, 2026

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic is expanding past its EHR into ERP, IT staffing, AI, drug pricing and payer technology. Delivery runs from tools live today to a full EpicOps rollout that may not arrive until 2029. The payer platform has the clearest proof point: St. Luke's and UnitedHealthcare automated status updates on 88% of the claims they exchanged.

  • 01Epic's payer platform is the expansion bet with a measured result: 88% of claim status updates automated between St. Luke's and UnitedHealthcare, plus a 25% drop in status calls.
  • 02EpicOps, Epic's ERP suite, may not be fully available until 2029, so a health system whose ERP commitments end sooner can test individual modules alongside its current system without a full switch.
  • 03Before using any integration with Epic's ambient AI, verify in your environment that the necessary write operations are supported, as FHIR support doesn't ensure full access.

Nov 16, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Mike Tracy
Mike Tracy

Chief Operating Officer at enGen

With a fulfilling history within the healthcare industry, Mike establish thoughtful, metric-based direction for new and improved initiatives, processes, and programs to refresh employee engagement, satisfy customers, and revamp operational efficiencies. By employing effective cost analysis, he identify avenues for appropriate cost reductions without jeopardizing staffing and operation needs. For example, Mike accomplished a 20% reduction in SG&A cost for technology by engineering a standard operating model, automation development, and revising processes in my current position. Alongside expert cost analysis, he ensure all implementations align with company goals and missions while assessing community needs.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512